openPR Logo
Press release

Real-World Evidence (RWE) Oncology Market Worth $1.65 Billion by 2029

06-03-2022 09:04 AM CET | Health & Medicine

Press release from: Meticulous Research®

According to a new market research report titled, 'RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), and End User (Pharma, Payer) - Global Forecast to 2029,' published by Meticulous Research®, the real-world evidence oncology solutions market is expected to grow at a CAGR of 14.2% from 2022-2029 to reach $1.65 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5276

Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications in oncology, including drug development life cycles, reducing development duration, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare.

Impact of COVID-19 on the RWE Oncology Solutions Market

The outbreak of the COVID-19 pandemic put a tremendous burden on healthcare sectors worldwide. The RWE oncology solutions market experienced an initial market shrinkage due to the impacts of the COVID-19 pandemic. The market shrinkage was attributed to factors such as the restrictions imposed on travel in several countries, the shifting of resources toward COVID-19 treatments in healthcare settings (including cancer care settings), and limited access to hospitals that disrupted the delivery of oncology services, including delayed diagnosis & treatment and clinical trial interruptions. These factors affected the amount of real-world data generated globally. The unavailability of treatment, patients, and resources significantly impacted the cancer care sector.

However, after the initial market shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology in cancer care. The FDA recognized the challenges posed by the COVID-19 pandemic to oncology trials. In September 2021, it issued a draft guidance on real-world data for evidence generation supporting regulatory decisions. This initiative promoted the adoption of RWE in clinical trials, and since then, RWD has been used increasingly in cancer progression mapping and patient profiling, clinical trials, drug development, post-market studies, treatment choice, dosing strategies, treatment sequencing, adverse event management, regulatory decision making, and financial burden associated with oncology treatment.

Thus, the COVID-19 pandemic negatively impacted the RWE oncology solutions market. However, RWD made a significant impact during the COVID-19 pandemic and continues to play a significant role in the treatment of cancer due to the initiatives taken by the FDA to promote RWE and support regulatory decision-making for drugs and biological products.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5276

The RWE oncology market is segmented based on component (real-world datasets and RWE consulting & analytics services), application (drug development & approvals, market access & reimbursement/coverage decisions, post-market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users), and geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes the market at the regional and country levels.

Based on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers. In addition, the growing need for evidence generated from real-world data and a shift from volume to value-based care has resulted in an increased focus on cancer registries, a rise in the adoption of EHR/EMR in hospitals, and exponential growth in mobile health data and social media, leading to the generation of huge amounts of medical data.

Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. Quality-of-life metrics and Patient-Reported Outcome Measures (PROMs) are becoming common elements in clinical trials for drug development. The evidence generated from real-world data is regularly utilized to inform aspects of drug development, such as the natural history and epidemiology of a disease, and provide data on treatment pathways and comparator interventions in clinical practice. The rising number of cancer cases has compelled pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, which is expected to drive the growth of this segment.

Quick Buy - "RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post Market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029" Research Report: https://www.meticulousresearch.com/Checkout/50669121

Based on end user, in 2022, the pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE oncology solutions market. The large share of this segment is attributed to the increasing importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The healthcare landscape continues to shift from volume to value-based care and is continuously developing. Pharmaceutical companies are focusing on new ways to provide the best treatments for cancer patients. Real-world evidence enables health care professionals and pharmaceutical companies to understand real-life clinical practices and actual health outcomes of drugs. Thus, pharmaceutical and biotech companies are increasingly utilizing real-world evidence to collect real-time post-trial information about drugs, enabling healthcare providers and researchers to understand the negative reactions, side effects, and medication errors related to the drugs, thereby allowing them to control the potential harm caused by the drugs.

Based on Geography, in 2022, North America is estimated to account for the largest share of the RWE oncology market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The high market growth in North America is attributed to the increasing number of cancer cases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, increased usage of electronic datasets, advanced healthcare industry, and the rising amount of big data in healthcare.

The key companies operating in the RWE oncology market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/rwe-oncology-market-5276

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Content Source: https://www.meticulousresearch.com/pressrelease/499/real-world-evidence-oncology-market-2029

We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

Through our mixed bag of research offerings - syndicated research, custom research, and analyst engagement - we enable smart decision making to enhance business performance for global organizations.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Real-World Evidence (RWE) Oncology Market Worth $1.65 Billion by 2029 here

News-ID: 2644172 • Views:

More Releases from Meticulous Research®

Software Defined Radio Market Trends, Insights, and Outlook | Meticulous Research®
Software Defined Radio Market Trends, Insights, and Outlook | Meticulous Researc …
The global software defined radio (SDR) market (Marché de la radio définie par logiciel) is gaining momentum as communication systems continue to evolve. Valued at $21.8 billion in 2024, the market is projected to reach $49.7 billion by 2035, growing at a CAGR of 7.8% from 2025 to 2035. This growth reflects the rising demand for advanced, flexible, and cost-efficient communication solutions across defense, commercial, and government sectors. Download Sample Report
Microgrid Implementation Market to Hit $142.8B by 2035 | Meticulous Research®
Microgrid Implementation Market to Hit $142.8B by 2035 | Meticulous Research®
Global Microgrid Implementation Market Outlook (2025-2035) The global microgrid implementation market is entering a period of remarkable expansion. Valued at USD 32.1 billion in 2024, the market is projected to grow to USD 36.8 billion in 2025, before reaching USD 142.8 billion by 2035. This translates to a compound annual growth rate (CAGR) of 14.5% during the forecast period. This growth reflects the rising importance of distributed energy systems, smart grid
Carbon Accounting Software Trends and Forecasts 2025-2032 | Meticulous Research®
Carbon Accounting Software Trends and Forecasts 2025-2032 | Meticulous Research …
Global Carbon Accounting Software Market Outlook (2025-2032) The carbon accounting software market is undergoing rapid transformation, driven by the urgent need for businesses to track, manage, and reduce their carbon footprints. Valued at USD 1.4 billion in 2024, the market is expected to reach USD 1.6 billion in 2025 and grow to nearly USD 7 billion by 2032, reflecting a strong compound annual growth rate of 23 percent. This surge highlights
Digital Fashion Market: Growth, Drivers, and Future Outlook | Meticulous Research®
Digital Fashion Market: Growth, Drivers, and Future Outlook | Meticulous Researc …
The global digital fashion market has entered a phase of rapid transformation. Valued at USD 1.1 billion in 2024, it is expected to climb to USD 1.4 billion in 2025 and further expand to USD 15.5 billion by 2035, growing at a striking CAGR of 27.2%. This surge is being fueled by the fusion of immersive technology, sustainable practices, and shifting consumer behavior. Unlike traditional fashion, digital fashion thrives on creativity

All 5 Releases


More Releases for RWE

Wood-Pellets Market Expected to Reach Nearly USD 9.0 Billion by 2031 | RWE Innog …
QYResearch A newly published report titled "Global Wood-Pellets Market 2025 is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Wood-Pellets market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and
U.S. Real-World Evidence (RWE) Solutions Market - Forecast to 2029
Meticulous Research®- leading U.S. market research company published a research report titled "U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029." Download Free Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5243 According to this latest publication from Meticulous Research®, the U.S. real-world evidence (RWE) solutions market is expected to grow at a CAGR of 13.1%
Real-world Evidence (RWE) Analytics Market Worth $2.93 billion by 2029
Meticulous Research®-a leading global market research company, published a research report titled, 'RWE Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) - Global Forecast to 2029'. Access Complete Free Sample PDF Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5306 According to this latest publication from Meticulous Research®, the global real-world evidence (RWE) analytics market is expected to grow
Sales of Real World Evidence/RWE Solutions Industry by 2031 | GIS
Global Real World Evidence/RWE Solutions Market report from Global Insight Services is the single authoritative source of intelligence on Real World Evidence/RWE Solutions Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data
Nuclear Power Plant Market Next Big Thing | Kepco, Magnox, RWE, Entergy
Nuclear power plant (NPP) uses nuclear fission reaction to heat water to produce steam which runs the turbines to generate electricity. The fission process occurs inside the reactor where uranium fuel is stored in its core. Considering the high fuel to output ratio produced by these power plants, countries are heavily investing in development of nuclear power plant. United States accounts for 20% of their total electricity production through nuclear
How RWE are making electric vehicles a reality in Europe
Electric Vehicles will play a significant role as a storage facility of renewable energy according to Joerg Lohr, Senior Manager E-Mobility at the global utility leader RWE Effizienz. Joerg Lohr is one of several global experts who will share his insight and experience at the upcoming Smart Utilities Australia and New Zealand conference and exhibition in Sydney from 8-10 November. During the event, Australia and New Zealand’s top